Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells

被引:52
作者
Jorcyk, Cheryl L.
Holzer, Ryan G.
Ryan, Randall E.
机构
[1] Boise State Univ, Dept Biol, Boise, ID 83725 USA
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Dept Vet Affairs Med Ctr, Boise, ID 83702 USA
[4] MSTMRI, Boise, ID 83702 USA
关键词
detachment; breast cancer; invasion; metastasis; OSM;
D O I
10.1016/j.cyto.2006.03.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oncostatin M (OSM), an IL-6 family cytokine, has previously been shown to increase migration of several breast cancer cell lines in vitro. Our studies report additional effects of OSM treatment on the human breast carcinoma cell line T-47D. OSM treatment alters T-47D cell morphology from a normal epithelial phenotype to a mesenchymal-like phenotype that is associated with cell detachment from substratum. These effects are also seen with H3922 human breast cancer cells. OSM treatment of T-47D cells for 5-8 days leads to a three-fold increase in cell detachment. OSM-induced detachment of T-47D cells is blocked by the protein kinase inhibitors UO126 and bisindolylmaleimide, indicating a role for MAP kinases and protein kinase C in OSM signaling events that regulate cell detachment. T-47D cells induced to detach by OSM have a reduced capacity to re-adhere to laminin in comparison to other extracellular matrix components. Detached multi-cell aggregates of T-47D cells are viable, whereas detached single cells appear apoptotic. In addition, OSM treatment induces the secretion of the lysosomal proteases cathepsins D and L from T-47D cells, which have been implicated in invasion and metastasis. Importantly, OSM-treated T-47D cells show a 250% increase in invasive capacity as measured by the Matrigel invasion chamber assay. Collectively, these data demonstrate that OSM induces a motile/invasive phenotype in T-47D cells in vitro, and suggest that OSM may enhance metastasis in vivo. Our results suggest that OSM itself may be a valid therapeutic target. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:323 / 336
页数:14
相关论文
共 80 条
[1]   Signaling of type II oncostatin M receptor [J].
Auguste, P ;
Guillet, C ;
Fourcin, M ;
Olivier, C ;
Veziers, J ;
PouplardBarthelaix, A ;
Gascan, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (25) :15760-15764
[2]  
Badache A, 2001, CANCER RES, V61, P383
[3]   Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells [J].
Barille, S ;
Akhoundi, C ;
Collette, M ;
Mellerin, MP ;
Rapp, MJ ;
Harousseau, JL ;
Bataille, R ;
Amiot, M .
BLOOD, 1997, 90 (04) :1649-1655
[4]   Cathepsin-D affects multiple tumor progression steps in vivo:: proliferation, angiogenesis and apoptosis [J].
Berchem, G ;
Glondu, M ;
Gleizes, M ;
Brouillet, JP ;
Vignon, F ;
Garcia, M ;
Liaudet-Coopman, E .
ONCOGENE, 2002, 21 (38) :5951-5955
[5]   Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J].
Bhowmick, NA ;
Ghiassi, M ;
Bakin, A ;
Aakre, M ;
Lundquist, CA ;
Engel, ME ;
Arteaga, CL ;
Moses, HL .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (01) :27-36
[6]  
Bohm Ingrid, 2003, Mol Imaging Biol, V5, P2, DOI 10.1016/S1536-1632(03)00024-6
[7]   Induction and regulation of epithelial-mesenchymal transitions [J].
Boyer, B ;
Vallés, AM ;
Edme, N .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1091-1099
[8]  
Brouillet JP, 1997, CANCER, V79, P2132, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2132::AID-CNCR10>3.3.CO
[9]  
2-L
[10]  
Bruce A. Gregory, 1996, P361